Zafgen (ZFGN) Stock Price, News & Analysis

Company Overview

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $3.11 to $3.55
• 50-Day Range: $0.99 to $25.06
• 52-Week Range: $0.62 to $2.76
• Volume: 855,250 shs
• Average Volume: 360,199 shs
• Market Capitalization: $118.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZFGN Stock Analysis - Frequently Asked Questions

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) announced its earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) EPS for the quarter, meeting analysts' consensus estimates of ($0.19).

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zafgen investors own include Xtrackers California Municipal Bond ETF (CA), Bristol Myers Squibb (BMY), Endologix (ELGX), Energy Transfer (ET), BlackRock (BLK), TG Therapeutics (TGTX) and SCYNEXIS (SCYX).

Company Calendar

• Last Earnings: 3/05/2020
• Today: 7/16/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ZFGN
• CIK: 1374690
• Web: www.zafgen.com
• Phone: 617-622-4003
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.34%
• Return on Assets: -34.55%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 6.56
• Quick Ratio: 6.56

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 2.34

Miscellaneous

• Outstanding Shares: 37,470,000
• Free Float: N/A
• Market Cap: $118.41 million
• Optionable: Not Optionable
• Beta: 0.27